A Phase 2 interventional study of MT-7117 low dose and MT-7117 high dose in Erythropoietic Protoporphyria (EPP), sponsored by Tanabe Pharma America, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is one of 5 in phase 2, and was the 9th registered.
29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.
Browse Protoporphyria, Erythropoietic studies →4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:
Portal Therapeutics, Inc. · Sites in United States
Ages 12+
Portal Therapeutics, Inc. · Sites in United States, Belgium, Canada and 6 more countries
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
Disc Medicine, Inc · Sites in United States, Australia, Belgium and 8 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 6
First in 2010; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 62 across 20 interventional studies indexed under Protoporphyria, Erythropoietic.
Median enrollment 77 across the 13 interventional studies, 150 across the 4 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tanabe Pharma America, Inc., one of the names counted as Tanabe Pharma Corporation. Under that name alone:
Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 2 studies filed under Protoporphyria, Erythropoietic — fewer than ten, so there is no comparison to draw.
1 of the studies in Protoporphyria, Erythropoietic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567131Portal Therapeutics, Inc.Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.
This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22. The total participation period is approximately 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional screening criteria check may apply for qualification.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-7117 low dose
Drug: MT-7117 high dose
Drug: Placebo
MT-7117 low dose QD, oral, 16 weeks
MT-7117 high dose QD, oral, 16 weeks
Placebo QD, oral, 16 weeks
Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16.
Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset. The average Duration in minutes, of sunlight exposure before the first prodromal symptom between 1 hour post sunrise and 1 hour pre-sunset. The average duration means that average of daily durations in 14-day windows before Day 1 (or week 16 Day) applied.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16
Change from baseline to week 16 in Average Daily Duration (Minutes) of Sunlight Exposure sums any sunlight exposure time excluding any overlapped time with prodromal symptoms, including if the patients go out multiple times on the same day after the prodromal symptom had previously ended.
Time frame: Baseline (Week 0), and Week 16
Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16
Change from baseline to week 16 in Average Daily Mean Duration (Minutes) of Sunlight Exposure without prodromal symptoms divided by the number of sunlight exposures periods applicable that day.
Time frame: Baseline (Week 0), and Week 16
Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period
Time frame: Week 16
Change From Baseline in Average Daily Mean Intensity of Prodromal Symptoms During 16-week Double-blind Treatment Period in 11-point Likert Scale
The Intensity of Prodromal Symptoms is measured by 11-point Likert scale ranges from 0 (no symptom) to 10 (greatest severity of symptom).
Time frame: Baseline (Week 0), and Week 16
Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period
Time frame: Baseline (Week 0), and Week 16
Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.
Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).
Time frame: Baseline (Week 0), Week 8, and Week 16
Percent Change From Baseline in Pigmentation as Measured by Melanin Density for Average of 6 Skin Segments at Week 8 and Week 16.
Time frame: Baseline (Week 0), Week 8, and Week 16
Total Number of Pain Events During 16-Week Double-Blind Treatment Period
Time frame: Week 16
Total Number of Sunlight Exposure Episodes
Time frame: Baseline (Week 0) and Week 16
Change in Pigmentation as Measured by Melanin Density
Time frame: Baseline (Week 0) and Week 16
The Quality of Life as Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 57
Time frame: Baseline (Week 0) and Week 16
| Milestone | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Started | 33 | 34 | 35 |
| Completed | 31 | 30 | 31 |
| Not completed | 2 | 4 | 4 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 4 |
| Withdrew: Cs adverse findings from post- baseline nevi evaluation | 0 | 1 | 0 |
Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset. The average Duration in minutes, of sunlight exposure before the first prodromal symptom between 1 hour post sunrise and 1 hour pre-sunset. The average duration means that average of daily durations in 14-day windows before Day 1 (or week 16 Day) applied.
| Minutes | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Change From Baseline in Average Daily Time (Minutes) to First Prodromal Symptom Associated With Sunlight Exposure Between Hour Post Sunrise and 1 Hour Pre-Sunset at Week 16. | 74.7 ± 76.8 | 92.4 ± 100 | 21.0 ± 63.4 |
Change from baseline to week 16 in Average Daily Duration (Minutes) of Sunlight Exposure sums any sunlight exposure time excluding any overlapped time with prodromal symptoms, including if the patients go out multiple times on the same day after the prodromal symptom had previously ended.
| Minutes | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Change From Baseline in Average Daily Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | 72.6 ± 76.2 | 86.1 ± 83.9 | 19.9 ± 63.2 |
Change from baseline to week 16 in Average Daily Mean Duration (Minutes) of Sunlight Exposure without prodromal symptoms divided by the number of sunlight exposures periods applicable that day.
| Minutes | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Change From Baseline in Average Daily Mean Duration (Minutes) of Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-Sunset Without Prodromal Symptoms at Week 16 | 70.2 ± 73.4 | 59.3 ± 85.2 | 12.8 ± 46.9 |
| sunlight exposure episodes | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Total Number of Sunlight Exposure Episodes With Prodromal Symptoms During 16-Week Double-Blind Treatment Period | 8.6 ± 9.3 | 7.7 ± 6.6 | 11.1 ± 13.3 |
The Intensity of Prodromal Symptoms is measured by 11-point Likert scale ranges from 0 (no symptom) to 10 (greatest severity of symptom).
| score on a scale | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Baseline | 2.0 ± 1.1 | 2.1 ± 0.9 | 2.0 ± 1.1 |
| Week 16 | 1.7 ± 1.1 | 2.4 ± 1.7 | 2.4 ± 1.4 |
| Minutes | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Change From Baseline in Average Daily Duration (Minutes) of Prodromal Symptoms at 16-Week Double-Blind Treatment Period | 55.3 ± 321.0 | 111.0 ± 466.1 | 83.3 ± 267.2 |
Pigmentation will be assessed in melanin density which are numeric scores measured by spectrophotometer on 6 skin segments (forehead, left cheek, right inside upper arm, left medial forearm, right-hand side of abdomen, and left-hand side of buttock).
| unitless | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Change from Baseline at Week 8 | 1.4635 ± 3.1644 | 1.6557 ± 2.2099 | 0.1390 ± 0.3376 |
| Change from Baseline at Week 16 | 1.1413 ± 0.7285 | 1.5307 ± 0.6881 | 0.1639 ± 0.3939 |
| percent change | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| % Change from Baseline at Week 8 | 30.4135 ± 32.8302 | 42.5543 ± 38.8390 | 4.2394 ± 11.9435 |
| % Change from Baseline at Week 16 | 44.0135 ± 43.7325 | 56.2871 ± 41.0660 | 7.4214 ± 16.7074 |
| pain events | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Total Number of Pain Events During 16-Week Double-Blind Treatment Period | 4.0 ± 6.4 | 3.3 ± 2.8 | 5.4 ± 4.9 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over All AEs and SAEs that occurred from the time written informed consent was obtained until the end of the follow-up period (6 weeks after the last treatment visit, for safety monitoring). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-7117 Low Dose | 0/33 (0%) | 1/33 (3%) | 31/33 (93.9%) |
| MT-7117 High Dose | 0/35 (0%) | 0/35 (0%) | 34/35 (97.1%) |
| Placebo | 0/34 (0%) | 0/34 (0%) | 31/34 (91.2%) |
| Event | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 1/33 | 0/35 | 0/34 |
| Event | MT-7117 Low Dose | MT-7117 High Dose | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/33 | 16/35 | 4/34 |
| EphelidesSkin and subcutaneous tissue disorders | 5/33 | 11/35 | 0/34 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 3/33 | 11/35 | 0/34 |
| NasopharyngitisInfections and infestations | 10/33 | 4/35 | 7/34 |
| HeadacheNervous system disorders | 6/33 | 10/35 | 6/34 |
| DiarrhoeaGastrointestinal disorders | 4/33 | 8/35 | 4/34 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/33 | 7/35 | 3/34 |
| FatigueGeneral disorders | 1/33 | 6/35 | 1/34 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 5/33 | 5/35 | 3/34 |
| Abdominal pain upperGastrointestinal disorders | 3/33 | 1/35 | 5/34 |
| Age, Continuous(years) | MT-7117 Low Dose | MT-7117 High Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 41.8 ± 12.8 | 41.9 ± 14 | 38.1 ± 12.6 | 40.6 ± 13.1 |
| Sex: Female, Male(Participants) | MT-7117 Low Dose | MT-7117 High Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 15 | 25 | 13 | 53 |
| Male | 18 | 9 | 22 | 49 |
| Ethnicity (NIH/OMB)(Participants) | MT-7117 Low Dose | MT-7117 High Dose | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 1 | 4 |
| Not Hispanic or Latino | 32 | 32 | 34 | 98 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MT-7117 Low Dose | MT-7117 High Dose | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 33 | 33 | 32 | 98 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Sep 2019, 14 months.
Results were first posted in Jan 2023, 3 years 3 months after primary completion. A results delay was requested in Sep 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dersimelagon
Protoporphyria, Erythropoietic →